In patients with early Alzheimer’s disease, donanemab resulted in a better composite score for cognition and for the ability to perform activities of daily living than placebo at 76 weeks, although results for secondary outcomes were mixed.

CSM-Protect

Safety and efficacy of riluzole in patients undergoing decompressive surgery for degenerative cervical myelopathy

adjuvant treatment for 6 weeks perioperatively with riluzole did not improve functional recovery beyond decompressive surgery in patients with moderate-to-severe degenerative cervical myelopathy

Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis

This trial found that ezogabine decreased excitability in ALS; further evaluation is warranted to determine whether longer treatment can sustain the effects on excitability and slow disease progression.

Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease

The study results suggest that in Alzheimer disease, plasma P-tau217 becomes abnormal before tau-PET and that plasma P-tau217 may be considered as an early Alzheimer disease biomarker.

Prevention of benign paroxysmal positional vertigo with vitamin D supplementation Supplementation of vitamin D and calcium may be considered in patients with frequent attacks of BPPV, especially when serum vitamin D is subnormal.

Safety and Efficacy of Extreme Blood Pressure Lowering in Intracerebral Hemorrhage Higher rates of neurologic deterioration and adverse events were associated with intensive treatment in patients with excessively high initial systolic blood pressure. ****

Autologous Hematopoietic Stem Cell Transplant in Multiple Sclerosis

Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis [BEAT-MS) is currently in progress.

Conclusions and Relevance  The National Multiple Sclerosis Society believes that AHSCT may be a useful treatment option for people with relapsing multiple sclerosis who demonstrate substantial breakthrough disease activity (ie, new inflammatory central nervous system lesions and/or clinical relapses) despite treatment with high-efficacy disease-modifying therapy or have contraindications to high-efficacy disease-modifying therapies. The best candidates are likely people younger than 50 years with shorter durations of disease (<10 years). The procedure should only be performed at centers with substantial experience and expertise. Ideally, recipients of the procedure should be entered into a single database, and further research is needed to establish ideal cell mobilization and immune-conditioning regimens.

NAVIGATE ESUS

Microbleeds and the Effect of Anticoagulation in Patients With Embolic Stroke of Undetermined Source.

Question - Does the presence of cerebral microbleeds (CMBs) modify the effect of rivaroxaban, 15 mg, compared with aspirin, 100 mg, daily in patients with embolic stroke of undetermined source (ESUS)?

Microbleeds mark an increased risk of recurrent stroke, ischemic stroke, intracerebral hemorrhage, and mortality in ESUS but do not appear to influence effects of rivaroxaban on clinical outcomes.

STROKE